Other General Flashcards
Baclofen belongs to which of the following drug classes?
Answers:
A. Dopaminergic agents
B. GABA Receptor agonists
C. NMDA-receptor antagonists
D. Selective serotonin reuptake inhibitors
E. Anticholinergic agents
GABA Receptor agonists
Discussion:
Baclofen is a GABA B receptor agonist that acts as an inhibitory neurotransmitter that blocks
monosynaptic and polysynaptic reflexes. Anticholinergic agents block acetylcholine from binding to
muscarinic receptors; examples include oxybutynin, which relaxes bladder smooth muscle cells.
NMDA-receptor antagonists include medications such as memantine as well as opioids such as
methadone. Dopaminergic agents include dopamine precursors, such as L-DOPA, reuptake
inhibitors and receptor agonists. Selective serotonin reuptake inhibitors (SSRIs) include widely
used antidepressants such as escitalopram and sertraline.
References:
McIntyre A, Mays R, Mehta S, et al. Examining the effectiveness of intrathecal baclofen on
spasticity in individuals with chronic spinal cord injury: a systematic review. J Spinal Cord Med.
2014 Jan;37(1):11-8. Khurana SR, Garg DS. Spasticity and the use of intrathecal baclofen in
patients with spinal cord injury. Phys Med Rehabil Clin N Am. 2014 Aug;25(3):655-69, ix. doi:
10.1016/j.pmr.2014.04.008. PMID: 25064793. Bolzoni F, Esposti R, Jankowska E, Hammar I.
Interactions Between Baclofen and DC-induced Plasticity of Afferent Fibers within the Spinal Cord.
Neuroscience. 2019 Apr 15;404:119-129. doi: 10.1016/j.neuroscience.2019.01.047. Epub 2019
Jan 31. PMID: 30710669. National Center for Biotechnology Information (2021). PubChem
Compound Summary for CID 2284, Baclofen. Retrieved May 23, 2021 from
https://pubchem.ncbi.nlm.nih.gov/compound/Baclofen.
Exposure to organophosphate insecticides produces neurologic symptoms because these
substances have which of the following effects?
Answers:
A. Reversible inhibition of acetylcholinesterase
B. Competitive antagonism of muscarinic acetylcholine receptors
C. Irreversible inhibition of acetylcholinesterase
D. Competitive antagonism of nicotinic acetylcholine receptors
E. Agonism of nicotinic acetylcholine receptors
Irreversible inhibition of acetylcholinesterase
Discussion:
Organophosphates irreversibly bind to and inhibit acetylcholinesterase at nicotinic and muscarinic
receptors leading to accumulation of ACh in the synaptic cleft resulting in over-stimulation of
nicotinic and muscarinic ACh receptors and impeded neurotransmission. The typical symptoms of
a cholinergic toxidrome are agitation, muscle weakness, muscle fasciculations, miosis,
hypersalivation, sweating, and diarrhea. Severe poisoning may cause respiratory failure, altered
consciousness, confusion, seizures, and/or death. An example of a reversible AChE inhibitor is
donepezil, a treatment for Alzeimer’s disease. Organophosphates do not exert their effects on the
receptors themselves. Antagonism of muscarinic ACh receptors is the mechanism of action of
atropine. Overdose of atropine can resut in an anti-cholinergic toxidrome (mydriasis, decreased
sweating, elevated temperature,tachycardia, changes in mental status). Antagonism of nicotinic
ACh receptors is the mechanism of action of many neuromuscular blocking drugs as antagonism
of the nicotinic receptors does not allow for depolarization thus effectively blocking muscle
contraction.
References:
Colović MB, Krstić DZ, Lazarević-Pašti TD, Bondžić AM, Vasić VM. Acetylcholinesterase inhibitors:
pharmacology and toxicology. Curr Neuropharmacol. 2013;11(3):315-335.
doi:10.2174/1570159X11311030006. Naughton SX, Terry AV Jr. Neurotoxicity in acute and
repeated organophosphate exposure. Toxicology. 2018 Sep 1;408:101-112. doi:
10.1016/j.tox.2018.08.011. Epub 2018 Aug 23. PMID: 30144465; PMCID: PMC6839762.
A 62-year-old man with a long-standing history of alcohol abuse is brought to the emergency
department because of disorientation and ataxia. Oral temperature is 33.9°C (93.0°F).
Examination shows horizontal gaze nystagmus. Immediate administration of which of the following
is most appropriate?
Answers:
A. glucose
B. flumazenil
C. thiamine
D. tPA
E. naloxone
thiamine
Discussion:
This patient appears to be experiencing Wernicke encephalopathy, an acute, reversible condition
caused by severe thiamine (vitamin B1) deficiency, often due to chronic heavy alcohol use.
Wernicke encephalopathy is an emergency and requires immediate high-dose IV thiamine therapy.
The classical triad of confusion, oculomotor dysfunction, and gait ataxia is seen in about a third of
patients. Chronic thiamine deficiency can progress to Korsakoff syndrome which is characterized
by irreversible personality changes, anterograde and retrograde amnesia, and confabulation.
Glucose administration should never occur before thiamine adnimistration as glucose increases
demand for thiamine thus worsening the patient’s encephalopathy.
References:
Latt N, Dore G. Thiamine in the treatment of Wernicke encephalopathy in patients with alcohol use
disorders. Intern Med J. 2014 Sep;44(9):911-5. doi: 10.1111/imj.12522. PMID: 25201422. Goetz C.
Textbook of Clinical Neurology. 2007.
The effects of abnormal lead absorption are most likely to be reflected by changes in the
Answers:
A. frontal lobes
B. peripheral nerves
C. spinal cord
D. hippocampus
E. cerebellum
peripheral nerves
Discussion:
The peripheral nerves are most commonly affected in adult lead poisoning. Although the CNS is
most commonly affected in children, adults with lead exposure typically present with a peripheral
polyneuritis most commonly affecting the extensor muscles suppled by the radial and peroneal
nerves. Foot drop and wrist drop are common clinical manifestations. Pathological changes
include segmental demyelination and axonal degeneration with concomitant endoneural edema of
Schwann cells. CNS injury can occur in adults with lead poisoning but the threshold is significantly
higher than for children.
References:
National Research Council. 1993. Measuring Lead Exposure in Infants, Children, and Other
Sensitive Populations. Washington, DC: The National Academies Press. https://doi.org/10.17226
/2232. Bressler J, Kim KA, Chakraborti T, Goldstein G. Molecular mechanisms of lead
neurotoxicity. Neurochem Res. 1999;24:595–600.
Which of the following neuropathic pain medications works by binding to voltage-gated calcium
channels in neurons?
Answers:
A. Diazepam
B. Gabapentin
C. Ketamine
D. Ketorolac
E. Methocarbamol
Gabapentin
Discussion:
Gabapentin demonstrates significant efficacy and success in the treatment of neuropathic pain.
The drug demonstrates high affinity for binding to voltage-gated calcium channels, particularly
alpha-2-delta-1, which thereby inhibits the release of excitatory neurotransmitters in the
presynaptic terminal. Ketorolac is a first-generation non-steroidal anti-inflammatory drug (NSAID)
which inhibits prostaglandin synthesis by competitively blocking the enzyme cyclooxygenase
(COX). The exact mechanism of action of methocarbamol is not established, however, it is
postulated to inhibit synaptic acetylcholinesterase. Diazepam is a benzodiazepime which
potentiates the inhibitory efect of γ-aminobutyric acid on neuronal transmission. Ketamine
functions as an NMDA receptor antagonist, however, its exact meechanism of action remains
unknown.
References:
1. Wiffen PJ, Derry S, Moore RA, et al. Antiepileptic drugs for neuropathic pain and fibromyalgia -
an overview of Cochrane reviews. Cochrane Database Syst Rev. 2013;11:CD010567.2. Chen L,
Mao J. Update on neuropathic pain treatment: ion channel blockers and gabapentinoids. Curr Pain
Headache Rep. 2013;17(9):359. Zamponi GW, Striessnig J, Koschak A, Dolphin AC. The
Physiology, Pathology, and Pharmacology of Voltage-Gated Calcium Channels and Their Future
Therapeutic Potential. Pharmacol Rev. 2015 Oct;67(4):821-70. doi: 10.1124/pr.114.009654. PMID:
26362469; PMCID: PMC4630564.
Baclofen, a drug that is used both orally and intrathecally in the treatment of spasticity, exerts its
action through which of the following means?
Answers:
A. GABA agonist
B. D2 Dopamine receptor agonist
C. 5-HT2B Agonism
D. GABA antagonist
E. NMDA-receptor antagonism
GABA agonist
Discussion:
Baclofen is a GABA agonist, acting by reducing the release of excitatory neurotransmitters and
substance P by binding to the GABA-B receptor. GABA antagonists include drugs that produce
stimulant or convulsant effects and are largely used to counteract overdoses of sedatives, such as
the GABA-A receptor antagonist flumazenil. D2 Dopamine receptor agonists include dopaminergic
drugs such as pramipexole which are utilized to treat symptoms of Parkinson’s Disease. NMDAreceptor antagonists include drugs such as ketamine, memantine and amantadine. Selective
serotonin reuptake inhibitors such as fluoxetine act as 5-HT2B agonists.
References:
Furr-Stimming E, Boyle AM, Schiess MC. Spasticity and intrathecal baclofen. Semin Neurol. 2014
Nov;34(5):591-6. doi: 10.1055/s-0034-1396012. Epub 2014 Dec 17. PMID: 25520030. Dvorak EM,
Ketchum NC, McGuire JR. The underutilization of intrathecal baclofen in poststroke spasticity. Top
Stroke Rehabil. 2011 May-Jun;18(3):195-202. doi: 10.1310/tsr1803-195. PMID: 21642057.
Chapter 64. In: Albright AL, Pollack IF, Adelson PD, eds. Principles and Practice of Pediatric
Neurosurgery. Thieme Medical Publishers:1160
The clinical triad of coma, pinpoint pupils, and depressed respiration is most consistent with
Answers:
A. Meningoencephalitis
B. Hyponatremia
C. Narcotic overdose
D. Seizure
E. Epidural hematoma
Narcotic overdose
Discussion:
The triad of coma, pinpoint pupils, and depressed respirations are most consistent with narcotic
overdose. All of the above answer choices are possible causes of coma but are not as likely as
narcotic overdose. A patient with a trauma causing an epidural hematoma will usually have
lateralizing signs. Additionally, although seizures, hypoglycemia, and infection may cause a
comatose or minimally reactive state, the triad of pinpoint pupils, decreased respirations, and
coma are not common in these situations.
References:
Boyer EW. Management of opioid analgesic overdose. N Engl J Med. 2012;367(2):146-155.
doi:10.1056/NEJMra1202561. Lalley PM. Opioidergic and dopaminergic modulation of respiration.
Respir Physiol Neurobiol. 2008 Dec 10;164(1-2):160-7. doi: 10.1016/j.resp.2008.02.004. PMID:
18394974; PMCID: PMC2642894. Stein C. The control of pain in peripheral tissue by opioids. N
Engl J Med 1995;332:1685-1690
Which of the following medications is most likely to include reversible cerebral vasoconstrictive
syndrome as a side effect?
Answers:
A. Aspirin
B. Rosuvastatin
C. Nimodipine
D. Metoprolol
E. Sertraline
Sertraline
Discussion:
Reversible cerebral vasoconstrictive syndrome (RCVS) is a clinical syndrome characterized by
acute thunderclap headache, emesis and nausea. RCVS is supposedly due to a transient
disturbance in the control of cerebrovascular tone. The syndrome demonstrates segmental
vasoconstriction on angiography and reversibility of the lesion. The syndrome is often triggered by
vasoactive substances, including selective serotonin reuptake inhibitors such as sertraline, or illicit
substances such as cocaine. More than half the cases occur post partum or after exposure to
adrenergic or serotonergic drugs. Manifestations have a uniphasic course, and vary from pure
cephalalgic forms to rare catastrophic forms associated with hemorrhagic and ischemic strokes,
brain edema, and death. The calcium channel blocker nimodipine seems to reduce thunderclap
headaches within 48 hr of administration, but has no proven effect on hemorrhagic and ischemic
complications.
References:
Ducros A, Boukobza M, Porcher R, et al. The clinical and radiological spectrum of reversible
cerebral vasoconstriction syndrome. A prospective series of 67 patients. Brain. 2007 Dec;130(Pt
12):3091-101. Ducros A. Reversible cerebral vasoconstriction syndrome. Lancet Neurol. 2012
Oct;11(10):906-17. doi: 10.1016/S1474-4422(12)70135-7. PMID: 22995694.
A 23-year-old woman with T2 quadriplegia is brought to the emergency department with increased
spasticity, dysphoria, pruritus, and a temperature of 40.6°C (105.0°F). Her spasticity has been
controlled with a baclofen pump implant for the past three years. She subsequently has a seizure
in the emergency department. Which of the following is the most likely diagnosis?
Answers:
A. Neuroleptic-Malignant Syndrome
B. Baclofen overdose
C. Malignant Hyperthermia
D. Autonomic Dysreflexia
E. Baclofen withdrawal
Baclofen withdrawal
Discussion:
Symptoms of intrathecal baclofen (ITB) withdrawal begin as a return of spasticity, rigidity and
pruritis. Abrupt withdraw, however, can prompt generalized seizures, hallucinations, muscle rigidity,
fevers, labile blood pressures and lethargy. If not treated promptly with supportive measures and
high-dose benzodiazeppine infusion prior to resumption of intrathecal baclofen therapy, the
syndrome can progress to include rhabdomyolysis (with markedly elevated plasma creatine kinase
levelsm, elevated transaminase levels, hepatic and renal failure, disseminated intravascular
coagulation, and rarely death.
ITB withdrawal is mediated by an abrupt decrease in central nervous synstem GABA transmission.
Autonomic dysreflexia is caused by disconnection of major splanchnic sympathetic outflow from
supraspinal control due to ongoing nociceptive stimulus below the level of a spinal cord lesion in a
T6 or higher spinal cord injury patient. Hallmarks include paradoxical bradycardia with
hypertension, the absence of fever, as well as piloerection and pallor below the level of injury with
flushing, vasodilation and profuse sweating above the SCI level. Malignant hyperthermia is
mediated by a ryanodine receptor mutation that causes calcium leakage from the sarcoplasmic
reticulum. It typically occurs in the setting of initiating anesthesias, particularly with halothane
agents, and presents as tetanic muscle contractions that are unresponsive to centrally acting
muscles relaxants. Although neuroleptic malignant syndrome also presents with profound
generalized rigidity, it is caused by an acute loss of hypothalamic dopaminergic transmission,
typically in the setting of initiating dopamine-blocking neuroleptic agents or after abrupt cessation
of a dopamine agonist. Clinical features also include hyperactive autonomic function, leukocytosis
at onset, tachycardia and hypertension. Overdosage of ITB is characterized by rostral progression
of hypotonia, respiratory depression, coma, and seizures in the absence of fevers and rigidity.
References:
Coffey R, Edgar T, Francisco G, Graziani V, Meythaler J, Ridgely P, Sadiq S, Turner M. Abrupt
withdrawal from intrathecal baclofen: recognition and management of potentially life-threatening
syndrome. Arch Phys Medical Rehabilitation 2002: 83:735-41.
Steinbok P. Neurosurgical Management of Hypertonia in Children. Neurosurgery Quarterly. 2002:
63-78
A 21-year-old art student is evaluated because of bilateral arm weakness. On examination, he
demonstrates 4/5 weakness in dorsiflexion of both wrists. His sensation is normal. He notes that
his latest project is creating painted ceramic coffee cups that he also uses for drinking. An EMG
shows evidence of a peripheral motor neuropathy causing the wrist drop. Administration of which
of the following is most likely to be the most appropriate treatment?
Answers:
A. iron
B. folate
C. observation alone
D. prednisone
E. penicillamine
penicillamine
Discussion:
This patient is most likely experiencing wrist drop secondary to peripheral neuropathy caused by
lead poisoning. The student may be unintentially ingesting lead by drinking from cups made with
lead-based paint. Lead poisoning typically causes a peripheral polyneuropathy that most
commonly affects the radial and peroneal nerves thus causing wrist or foot drop. Other common
symptoms of lead poisoning include cognitive impairment, anemia, abdominal pain, and
constipation. In addition to removing exposure to the offending lead-based paint, this patient may
be treated with a chelating agent such as penicillamine if their blood lead levels are elevated.
References:
Kim HC, Jang TW, Chae HJ, et al. Evaluation and management of lead exposure. Ann Occup
Environ Med. 2015;27:30. Published 2015 Dec 15. doi:10.1186/s40557-015-0085-9. Bressler J,
Kim KA, Chakraborti T, Goldstein G. Molecular mechanisms of lead neurotoxicity. Neurochem Res.
1999;24:595–600. Vij A. Hemopoietic, hemostatic and mutagenic effects of lead and possible
prevention by zinc and vitamin C. Al Ameen J Med Sci. 2009;2:27–36.
Which of the following pharmacologic agents acts as an extracerebral decarboxylase inhibitor?
Answers:
A. Carbidopa
B. Phenylalanine
C. Levodopa
D. Pyridoxine
E. Tyrosine
Carbidopa
Discussion:
Extracerebral decarboxylase inhibitors such as carbidopa inhibit peripheral metabolism of
levodopa. This allows a greater proportion of peripheral levodopa to cross the blood–brain barrier
and be utilized in the brain rather than metabolized peripherally. Levodopa is used to increase
dopamine concentrations in the brain for the treatment of Parkinson’s disease and dopamineresponsive dystonia. Coadministration of pyridoxine without an extracerebral decarboyxlase
inhibitor accelerates the peripheral decarboxylation of Levodopa to such an extent that it negates
the effects of levodopa administration. Levodopa is produced from the amino acid l-tyrosine by the
enzyme tyrosine hydroxylase.
References:
Calne, D. B.; Reid, J. L.; Vakil, S. D.; Rao, S.; Petrie, A.; Pallis, C. A.; Gawler, J.; Thomas, P. K.;
Hilson, A. (1971). “Idiopathic Parkinsonism treated with an extracerebral decarboxylase inhibitor in
combination with levodopa.” British Medical Journal. 3 (5777):
729–732. doi:10.1136/bmj.3.5777.729. PMC 1798919. PMID 4938431. Gershanik OS. Improving
L-dopa therapy: the development of enzyme inhibitors. Movement Disorders : Official Journal of
the Movement Disorder Society. 2015 Jan;30(1):103-113. DOI: 10.1002/mds.26050.
The most common manifestation of alcohol withdrawal syndrome is
Answers:
A. peripheral neuropathy
B. ataxia
C. hallucinations
D. seizures
E. autonomic hyperactivity
autonomic hyperactivity
Discussion:
The most common symptoms of alcohol withdrawal syndrome of the choices are autonomic
changes. Alcohol withdrawal syndrome will manifest with tachycarcardia, fever, and other signs of
autonomic hyperactivity. These symptoms can begin as early as 6 hours after the patient has last
consumed alcohol. Seizures and hallucinations can also occur, but these findings are less
common and typically occur later in the course of alcohol withdrawal. Peripheral neuropathy and
ataxia are not typically associacted with alcohol withdrawal but rather chronic alcohol misuse.
Peripheral neuropathy can occur with a megaloblastic anemia secondary to cobalamin deficiency
and ataxia may result from Korsakoff syndrome and chronic thiamine deficiency.
References:
Mirijello A, D’Angelo C, Ferrulli A, Vassallo G, Antonelli M, Caputo F, Leggio L, Gasbarrini A,
Addolorato G. Identification and management of alcohol withdrawal syndrome. Drugs. 2015
Mar;75(4):353-65. doi: 10.1007/s40265-015-0358-1. PMID: 25666543; PMCID: PMC4978420.
McKeon A, Frye MA, Delanty N. The alcohol withdrawal syndrome. J Neurol Neurosurg Psychiatry.
2008 Aug;79(8):854-62. doi: 10.1136/jnnp.2007.128322. Epub 2007 Nov 6. PMID: 17986499.
Sachdeva A, Choudhary M, Chandra M. Alcohol Withdrawal Syndrome: Benzodiazepines and
Beyond. J Clin Diagn Res. 2015 Sep;9(9):VE01-VE07. doi: 10.7860/JCDR/2015/13407.6538.
Epub 2015 Sep 1. PMID: 26500991; PMCID: PMC4606320.
In 2009, the United States Food and Drug Administration mandated updated labeling for all
anticonvulsant medications to indicate an increased risk of which of the following?
Answers:
A. Weight Gain
B. Dystonia
C. Stevens-Johnson Syndrome
D. Suicidal Ideation
E. Aplastic Anemia
Suicidal Ideation
Discussion:
In 2008, the FDA conducted a meta-analysis of 199 placebo-controlled trials of 11 antiepileptic
agents, including gabapentin, divalproex, felbamate, lamotrigine, levetiracetam, oxcarbazepine,
pregabalin, tiagabine, topiramate, zonisamide, and carbamazepine. Of the 43,892 patients
captured, the risk of suicidality was twice as likely in patients receiving these medications relative
to placebo controls (0.43% versus 0.22%). Risks were found to increase soon after initiation of the
agent and persisted through at least six months of use. The FDA subsequently issued a safety
mandate warning of suicidal ideation and risk associated with antiepileptic medications.
Depression is not uncommon among patients with chronic epilepsy, however, suicidality has not be
shown to correlate with the severity of illness. Recognition of this risk should be considered and
patients starting anticonvsulvie medication for any indication should be counseled appropriately.
References:
Arana A, Wentworth CE, Ayuso-Mateos JL, et al. Suicide-related events in patients treated with
antiepileptic drugs. N Engl J Med. 2010 Aug 5;363(6):542-551.
Mula M, Kanner AM, Schmitz B, Schachter S. Antiepileptic drugs and suicidality: an expert
consensus statement from the Task Force on Therapeutic Strategies of the ILAE Commission on
Neuropsychobiology. Epilepsia 2013;54:199-203.
Hesdorffer DC, Kanner AM. The FDA alert on suicidality and antiepileptic drugs: fire or false
alarm? Epilepsia 2009;50:978-986.
A patient who takes vitamin supplements reports headaches, diplopia, and diffuse myalgias.
Examination shows papilledema and dry, scaly skin. The patient is most likely consuming an
excess of which of the following vitamins?
Answers:
A. Niacin
B. Vitamin A
C. Pyridoxine
D. Vitamin E
E. Vitamin C
Vitamin A
Discussion:
The clinical scenario best describes a patient with chronic vitamin A toxicity. Vitamin C toxicity can
lead to GI symptoms, fatigue, and nephrolithiasis due to increased calcium oxalate formation.
Vitamin E toxicity is rare but can cause increased risk of bleeding and coagulopathy as high doses
may alter Vitamin K metabolism. Niacin and Pyridoxine are B vitamins which can be associated
with facial flushing and sensory peripheral neuropathy when taken in excess, respectively.
References:
Penniston KL, Tanumihardjo SA. The acute and chronic toxic effects of vitamin A. Am J Clin Nutr.
2006 Feb;83(2):191-201. doi: 10.1093/ajcn/83.2.191. PMID: 16469975. Leo MA, Lieber CS.
Alcohol, vitamin A, and beta-carotene: adverse interactions, including hepatotoxicity and
carcinogenicity. Am J Clin Nutr. 1999 Jun;69(6):1071-85. doi: 10.1093/ajcn/69.6.1071. PMID:
10357725. Olson JM, Ameer MA, Goyal A. Vitamin A Toxicity. 2021 Feb 11. In: StatPearls
[Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan–. PMID: 30422511
A 65-year-old man has a 10-year history of complex partial seizures that are uncontrolled with
carbamazepine at standard therapeutic levels. He also is being treated for chronic atrial fibrillation
with warfarin. Which of the following medications is the most appropriate substitution for the
carbamazepine?
Answers:
A. Phenobarbital
B. Valproic Acid
C. Leviteracetam
D. Phenytoin
E. Primidone
Leviteracetam
Discussion:
Carbamazepine, phenytoin, phenobarbital and primidone (henceforth referred to collectively as
enzyme-inducing AEDs) stimulate the activity of a variety of cytochrome P450 (CYP) enzymes,
including CYP1A2, CYP2C9, CYP2C19 and CYP3A4, as well as glucuronyl transferases (GT) and
epoxide hydrolase. Because these enzymes are involved in the biotransformation of the majority of
therapeutic agents, patients taking enzyme inducing AEDs metabolize at a faster rate a wide range
of concomitantly administered medications, whose dosage requirements may be consequently
increased. Valproic acid differs from other older generation AEDs in being an inhibitor rather than
an inducer of drug metabolizing enzymes, including those involved in the oxidation of
phenobarbital, the glucuronidation of lamotrigine and the conversion of carbamazepine-10,11-
epoxide to the corresponding diol, epoxide hydrolase. Levetiracetam, gabapentin and pregabalin
have not been reported to cause or be a target for clinically relevant pharmacokinetic drug
interactions.
References:
Juurlink DN. Drug interactions with warfarin: what clinicians need to know. CMAJ
2007;177:369-71. Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin
Pharmacol 2005; 61:246-55. The Treatment of Epilepsy, ed Shorrons et al. 2004. p. 443-450.